Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing a second consecutive day of decline, with the TCM ETF (560080) dropping by 1.13% and a total trading volume exceeding 71 million yuan, indicating a potential buying opportunity as it has attracted over 86 million yuan in the last two days [1][3]. Group 1: Market Performance - The TCM ETF (560080) has seen a decline in key constituent stocks, with Yunnan Baiyao and China Resources Sanjiu both falling over 1%, while Yiling Pharmaceutical dropped over 3%. Conversely, Jilin Aodong rose over 1% [3]. - The TCM ETF's tracked index has a current price-to-earnings (PE TTM) ratio of 24.22, which is below 83.72% of the time since its inception in May 2015, indicating a favorable valuation [6]. Group 2: Earnings Forecasts - As of January 25, 2026, 11 TCM listed companies have released their 2025 annual reports and earnings forecasts, with 6 companies showing positive year-on-year net profit growth. Notably, 3 companies have growth rates exceeding 100% [7]. - The primary drivers for the earnings growth include the establishment of a "hospital + external" collaborative development model, with a focus on enhancing external market channels, particularly e-commerce [7]. Group 3: Policy and Structural Changes - The basic drug catalog has completed preliminary expert selection, with significant adjustments expected in 2026. The current catalog, last updated in 2018, includes 685 varieties, of which 268 are traditional Chinese medicines [7]. - The upcoming adjustments to the basic drug catalog are anticipated to enhance the accessibility of grassroots medications and promote a "1+X" medication model, potentially leading to rapid market expansion [7]. Group 4: Investment Themes - Three main investment themes in the TCM sector are highlighted: 1. Price governance, focusing on price reductions and market share in the context of centralized procurement and insurance negotiations [8]. 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, benefiting TCM sales [9]. 3. State-owned enterprise reform, which is expected to yield performance improvements and investment opportunities in the TCM sector [9].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002317 | 众生药业 | 19.81 | -8.16% | 92.14万 | 18.75 Z | | 002728 | 特一药业 | 12.95 | -6.43% | 93.80万 | 12.32 Z | | 300878 | 维康药业 | 27.14 | -3.83% | 4.93万 | 1.35亿 | | 002603 | 以岭药业 | 18.34 | -3.58% | 50.24万 | 2662.6 | | 002864 | 盘龙药业 | 34.79 | -3.50% | 4.97万 | 1.74亿 | | 002198 | 嘉应制药 | 7.10 | -3.27% | 26.27万 | 1.89亿 | | 600594 | 益佰制药 | 4.04 | -3.12% | 24.79万 | 1.01亿 | | 002644 | 佛慈制药 | 8.81 | -2.97% | 9.60万 | 8527.07万 | | 600222 | 太龙药 ...

Core Viewpoint - The Henan Province has issued a notification to enhance the quality of traditional Chinese medicine (TCM) and promote the high-quality development of the TCM industry through various policy measures [1] Group 1: Industry Development - The policy aims to optimize the layout of the TCM industry in Henan Province [1] - Support will be provided for the construction of the Central Plains Medical Science City and the Provincial Academy of Traditional Chinese Medicine to create a health industry hub [1] - The goal is to cultivate 3 to 5 TCM enterprises with annual revenues exceeding 3 billion yuan (approximately 0.46 billion USD) and to build a nationally influential TCM industry cluster [1] Group 2: Small and Medium Enterprises - The initiative includes the development of specialized and innovative small and medium-sized enterprises in the TCM sector [1] - The policy encourages the "TCM+" approach to promote the extension of the industrial chain and enhance the supply of high-quality health food and medicinal products [1] Group 3: Specific Industry Focus - Support will be given to the full-chain development of single medicinal industries such as Nanyang mugwort and Jiaozuo Huai medicine [1] - The province aims to seek the establishment of national collaborative innovation pilot projects in the TCM industry [1]

Core Viewpoint - China Traditional Chinese Medicine (0570.HK) experienced a decline of 4.57%, closing at HKD 2.09, with a trading volume of HKD 95.08 million and a market capitalization of HKD 10.5 billion. The company announced a projected loss for the fiscal year ending December 31, 2025, marking a significant shift from profit to loss, with expected losses between RMB 350 million to RMB 500 million, compared to a profit of RMB 20.77 million in the previous year. Adjusted net profit is anticipated to decrease by 45% to 55%, down from RMB 636 million in the prior year [1][1][1] Financial Performance - The company expects to report a loss for the fiscal year 2025, which would be the first loss since 2013 [1] - The adjusted net profit is projected to decline by 45% to 55%, with the previous year's figure being approximately RMB 636 million [1] Analyst Ratings - Morgan Stanley has updated its risk-reward rating for China Traditional Chinese Medicine, lowering earnings forecasts for 2026 to 2030 by 5% to 12% and reducing the target price from HKD 1.5 to HKD 1.4, maintaining a "Reduce" rating [1][1] - The firm believes there is a 70% to 80% probability that the stock price will decline over the next 30 days, primarily due to the profit warning [1][1] Market Outlook - The company faces challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - The market currently has low visibility regarding the company's performance in 2026, indicating further potential downside for the stock price [1]

摩根士丹利发布研报称，已更新中国中药(00570)风险回报评级，在其2025年初步业绩公告后，基于预 期销售额与毛利率下调，将2026至2030年的盈利预测下调5%至12%。其目标价及悲观假设估值相应下 调7%;目标价由1.5港元下调至1.4港元;评级"减持"。 ...

第一：贵金属继续大涨 连续震荡几天后，终于获得了足够的推动了，继续上涨。上场吗？ 对我来说，这不是选择题，因为看不懂的地方，根本不用思考，继续等待就可以。 据圈友所说，现在很多平时不炒股、开了户放着的朋友都开始炒起股来了。别人贪婪了，我们要恐惧吗？ 据说2005年、2015年都发生过类似的情况，这次呢？我也不知道。但我知道，自己看不懂、看不透、无法理解核心技术的行业，我是赚不到钱的。 板块上： 第二：CRO大跌 之前准备做CRO的时候，没有等来合适的机会，结果错过了一大波大涨。 我也没着急追上去，继续等待下一次的机会，这不，机会又来了。这个市场根本不缺机会，只要你有足够的耐心和金钱。 第三：中药还是不行 昨晚，中药龙头片出来维护股价，提出未来半年内，将出3亿至5亿用于增持。 结果今天仅仅一个高开，然后又是大步下跌，这谁能受得了。业绩不好，看不到前景，这是最难的。 不着急搞大仓位。 我是李聪，10年读书会主理人，活到老、学到老，关注我，一起向上成长！ 以上仅为个人看法，不作为任何建议！ 隔夜的黄金、白银继续创下新高，黄金涨破5100美金/盎司，白银突破110美金/盎司，均是历史首次。 对应的，美元指数却跌到了4 ...

Group 1: Company Overview - Luweizhai, founded in 1927, is a time-honored brand specializing in the research, production, and sales of marinated food products [1] - The company has innovatively created a "museum cluster" that combines rich history with modern experiences [1] - The third-generation inheritors maintain traditional methods while integrating smart production lines [1] Group 2: Marketing and Consumer Engagement - Luweizhai has established seven themed live streaming rooms, incorporating "happiness culture" into sales, with the chairman's live stream attracting up to 800,000 viewers per session [1] - The company aims to appeal to younger consumers by developing low-salt and innovative flavors, which accounted for 30% of store sales within three months of launch [1] Group 3: Industry Trends and Innovations - The rise of "light health" trends has prompted companies like Huaren Jiangzhong, known for its digestive tablets, to enter the market with modern health products [3][6] - Huaren Jiangzhong invests over 10% of its annual revenue in research and development, establishing national-level research platforms to modernize traditional health wisdom [6][8] Group 4: Cultural Significance and Community Impact - The production of traditional glutinous rice cakes in Hunan's Xupu County has evolved into an industry that supports rural revitalization, transforming local customs into a thriving business [10][12] - The glutinous rice cakes, once a household tradition, are now marketed nationwide through e-commerce, enhancing community livelihoods [12]

近日，中国中药发布公告称，预计2025年本集团将由盈转亏，亏损净额区间预估约为3.5亿元至5亿元， 而上年同期的盈利净额约为2077万元。同时，本期经调整盈利净额预计同比下降45%至55%，上年同期 约为6.36亿元。 董事会表示，上述事项不会对本集团的持续经营能力产生不利影响，并强调所提及的经调整盈利净额并 未在香港财务报告准则中界定。股东及潜在投资者应注意本公告所载信息为初步评估，最终业绩公告预 计于2026年3月底前发布。 亏损的主要原因包括中药配方颗粒业务收入规模及盈利能力下降。此外，本期商誉减值、无形资产减值 及信用减值增加。 （中国中药公告） (编辑：杨燕 林辰) ...

Group 1 - Morgan Stanley believes that the stock price of Chinese traditional medicine will decline in the next 30 days, with a probability estimated between 70% to 80% [1] - The rating is set to "Underweight" with a target price of HKD 1.5 [1] - The expected stock price movement is attributed to a profit warning, as the company anticipates a loss for the fiscal year 2025, marking the first occurrence since 2013 [1] Group 2 - The company is facing challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - As a result, market visibility regarding the company's performance in 2026 is low, leading to expectations of further downside potential for the stock price [1]

证券日报网讯 1月27日，吉林敖东（000623）在互动平台回答投资者提问时表示，在现金分红方面，公 司始终重视股东回报，坚持稳健的利润分配原则，2022年度、2023年度、2024年度公司现金分红及股份 回购总额分别为5.08亿元、8.68亿元、8.91亿元，分别占2022年度、2023年度、2024年度合并口径归属 于母公司股东净利润的28.54%、59.43%、57.43%。公司已经连续18年现金分红，上市以来累计现金分 红47.39亿元。公司未来具体分红方案将结合经营发展、资金状况等综合情况，履行法定审议及信息披 露程序，相关事项请以公司在巨潮资讯网等法定渠道披露的公告为准。 ...